Incyte Co. (NASDAQ:INCY) EVP Sheila A. Denton Sells 14,069 Shares

Incyte Co. (NASDAQ:INCY) EVP Sheila A. Denton sold 14,069 shares of Incyte stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the completion of the sale, the executive vice president now owns 25,848 shares of the company’s stock, valued at $1,914,561.36. This trade represents a 35.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Incyte Price Performance

NASDAQ INCY traded up $0.32 during trading hours on Friday, reaching $73.50. The company’s stock had a trading volume of 1,489,085 shares, compared to its average volume of 1,608,318. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The company’s 50-day moving average is $71.68 and its two-hundred day moving average is $69.75. The firm has a market capitalization of $14.22 billion, a price-to-earnings ratio of 272.23, a P/E/G ratio of 0.41 and a beta of 0.70.

Incyte (NASDAQ:INCY) last announced its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, equities analysts predict that Incyte Co. will post 4.86 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on INCY. Royal Bank of Canada dropped their price objective on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a report on Tuesday, February 11th. Wells Fargo & Company boosted their price target on Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. JMP Securities restated a “market perform” rating on shares of Incyte in a research note on Tuesday, February 11th. Stifel Nicolaus upped their target price on Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a research report on Monday, February 10th. Finally, William Blair reissued an “outperform” rating on shares of Incyte in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Incyte currently has a consensus rating of “Hold” and an average target price of $75.25.

Institutional Trading of Incyte

Several institutional investors have recently modified their holdings of the stock. CWA Asset Management Group LLC acquired a new stake in Incyte in the 4th quarter worth about $1,933,000. Orion Portfolio Solutions LLC acquired a new stake in shares of Incyte in the third quarter worth approximately $770,000. Greenwood Capital Associates LLC acquired a new stake in shares of Incyte in the third quarter worth approximately $433,000. Tri Ri Asset Management Corp purchased a new stake in shares of Incyte during the third quarter worth approximately $3,292,000. Finally, Cypress Capital Group acquired a new position in Incyte in the 3rd quarter valued at $971,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.